Today, the U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers. Padcev is indicated for the treatment of adult patients with locally […]
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. Zanubrutinib is a small molecule inhibitor of Bruton tyrosine […]
The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many cancers including NSCLC. These drugs are designed to help the immune system recognize and fight cancer. Opdivo belongs to a class of medicines […]
Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor demonstrate that with 25 months of follow up Alunbrig continues to demonstrate overall and intracranial effectiveness compared […]
PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer
Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer according to the results of the phase 3 PAOLA-1/ENGOT-ov25 study presented at the European Society for Medical Oncology (ESMO) Congress 2019. (1) About Lynparza […]
Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with nicotine for 54 weeks developed lung adenocarcinomas. None of the 20 mice from the study […]
Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA clinical trial presented at the ESMO Congress in Oct 2019. (1,2) the median overall survival with osimertinib was 38.6 months compared to 31.8 […]
Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the study, Thomas E. Stinchcombe, MD, Duke Cancer Institute, Durham, North Carolina, and colleagues sought to determine whether adding bevacizumab to standard […]
A recent study supports what individuals with polycythemia vera (PV) have known for years. PV associated symptoms are underappreciated by doctors and don’t necessarily correlate with blood counts levels. Individuals with PV can experience symptoms of fatigue, itching, weakness, headaches and other symptoms despite being on medication. All too often physicians don’t appreciate the severity […]
Dr. Tanios Bekaii- Saab, MD, Program Head Mayo Clinic answered questions about management of advanced colo-rectal cancer CancerConnect and The Personalized Medicine Foundation were pleased to provide patients and caregivers the opportunity to ask questions about the management of advanced colo-rectal cancer with Dr Tanios Bekaii-Saab, MD FACP Head-Mayo Clinic Gastrointestinal Cancer Program & Director […]
The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and are not candidates for curative surgery or radiation. The 111/KEYNOTE-146 single-arm clinical trial […]
Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic myeloid leukemia (CML) is a cancer that originates in the immune cells. In CML large numbers of young immune […]
The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to randomized phase 3 study results presented at ASCO Annual Meeting. Isatuximab (Sanofi) is a novel anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells, including direct […]
Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been released and the combination delays cancer progression. (1) About Ovarian Cancer Ovarian cancer is the eighth most common […]
